U.S. markets open in 6 hours 24 minutes
  • S&P Futures

    4,207.00
    -16.00 (-0.38%)
     
  • Dow Futures

    33,869.00
    -148.00 (-0.44%)
     
  • Nasdaq Futures

    13,914.00
    -67.25 (-0.48%)
     
  • Russell 2000 Futures

    2,298.10
    -12.00 (-0.52%)
     
  • Crude Oil

    71.77
    -0.38 (-0.53%)
     
  • Gold

    1,815.90
    -45.50 (-2.44%)
     
  • Silver

    27.07
    -0.74 (-2.67%)
     
  • EUR/USD

    1.1985
    -0.0148 (-1.22%)
     
  • 10-Yr Bond

    1.5690
    0.0000 (0.00%)
     
  • Vix

    18.15
    +1.13 (+6.64%)
     
  • GBP/USD

    1.3992
    -0.0091 (-0.64%)
     
  • USD/JPY

    110.6700
    +0.6360 (+0.58%)
     
  • BTC-USD

    39,159.80
    -1,290.71 (-3.19%)
     
  • CMC Crypto 200

    973.61
    -18.86 (-1.90%)
     
  • FTSE 100

    7,184.95
    0.00 (0.00%)
     
  • Nikkei 225

    29,018.33
    -272.68 (-0.93%)
     

Evolus Shares Surge After Settling Jeuveau Related Litigation With AbbVie, Medytox

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Evolus Inc (NASDAQ: EOLS), AbbVie Inc (NYSE: ABBV), and Medytox announced settlement agreements to fully resolve all outstanding litigation, including the United States International Trade Commission (ITC) case regarding the sale of Jeuveau. It is a prescription medicine injected into muscles and used in adults temporarily to improve the look of moderate to severe frown lines between the eyebrows (glabellar lines).

  • A California court case filed by Medytox against Evolus will be dismissed.

  • Under the terms of the settlement agreements, AbbVie and Medytox will release all claims against Evolus related to the alleged misappropriation of Medytox's trade secrets and grant a license to Evolus to continue to commercialize Jeuveau in the U.S. and Nuceiva.

  • AbbVie and Medytox will receive milestone and royalty payments from Evolus. Besides, Evolus will issue common stock to Medytox.

  • Price Action: EOLS gained sharply by 45.3% at $10.05, while ABBV is down 0.53% at $105.5 in market trading hours on last check Friday. 

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.